findmyKOL
Clinical trialNCT07130695RecruitingPhase 1Interventional

Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation

SponsorVirginia Commonwealth UniversityEnrollment15Acute Myeloid Leukemia
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Virginia Commonwealth University

    Richmond, Virginia, United States

    Keri Maher, DO
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
2 Feb 2026
Primary completion
31 Oct 2028
Completion
31 Oct 2030
Last update posted
6 Feb 2026
Registered enrollment
15
Registry id
NCT07130695
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.